Home Newsfeeds Twitter Fired More Than 90% of India Staff

Twitter Fired More Than 90% of India Staff

-Bloomberg https://www.bloomberg.com/news/articles/2022-11-07/twitter-fires-more-than-90-of-india-staff-leaving-just-a-dozen?leadSource=uverify%20wall

byCharles Gross

November 7, 2022

1 minute read

-Bloomberg

https://www.bloomberg.com/news/articles/2022-11-07/twitter-fires-more-than-90-of-india-staff-leaving-just-a-dozen?leadSource=uverify%20wall

News

Tesla, Carvana Tag Team: Model 3 Claims Used EV Sales Crown Once Again

By Adam Eckert

July 10, 6:13 PM

Electric vehicle sales through Carvana Co (NYSE: CVNA) continue to accelerate and Tesla Inc (NASDAQ: TSLA) is

CVNA

Sana Biotechnology Q3 EPS $(0.48) Down From $(0.37) YoY

By Benzinga Newsdesk

November 2, 5:31 PM

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.48) per share. This is a 29.73 percent decrease over losses of $(0.37) per share from the same period last year.

SANA

Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH

By Benzinga Newsdesk

May 16, 4:02 PM

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review

IVA

The UK National Institute For Health And Care Excellence Issues Final Draft Guidance To Provide Patients With A Natural Lens Being Treated For Chronic Diabetic Macular Edema Access To ILUVIEN

By Benzinga Newsdesk

February 8, 9:01 AM

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,

ALIM

Twitter Fired More Than 90% of India Staff

Related Posts

Tesla, Carvana Tag Team: Model 3 Claims Used EV Sales Crown Once Again

Sana Biotechnology Q3 EPS $(0.48) Down From $(0.37) YoY

Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH

The UK National Institute For Health And Care Excellence Issues Final Draft Guidance To Provide Patients With A Natural Lens Being Treated For Chronic Diabetic Macular Edema Access To ILUVIEN